Posted in

Are Biological Grafts Safe for Sacrocolpopexy Surgery?

•Posted inObstetrics and Gynaecology

Surgeons often use MISC biological grafts to treat pelvic organ prolapse while avoiding mesh complications. However, recent evidence suggests that these materials may not offer the same durability as synthetic options. This systematic review analyzes how different biological grafts perform in minimally invasive sacrocolpopexy.

The meta-analysis evaluated five major studies involving 353 patients. Researchers found that recurrence rates for pelvic organ prolapse were significantly higher than those typically seen with synthetic mesh. Specifically, the pooled recurrence rate reached 25.6%. This high failure rate raises concerns about the long-term effectiveness of these materials in clinical practice. Furthermore, the risk of reoperation for recurrence was nearly 17%.

Comparing Outcomes of MISC Biological Grafts

Different biological materials showed vastly different outcomes in the review. For instance, acellular dermal matrix (ADM) performed relatively well with only a 2.4% recurrence rate. In contrast, cadaveric fascia lata resulted in recurrence for over half of the patients. Therefore, surgeons must carefully select the specific graft type based on individual patient needs. Fortunately, graft exposure remains rare, occurring in less than 1% of cases. Consequently, physicians should weigh the benefits of reduced exposure against the risk of surgical failure.

Frequently Asked Questions

Q1: Do biological grafts have fewer complications than synthetic mesh?

Yes, biological grafts generally have lower rates of exposure and immunologic reactions compared to traditional synthetic meshes. However, they carry a higher risk of prolapse recurrence.

Q2: Which biological graft performed best in the study?

The study found that Acellular Dermal Matrix (ADM) had the lowest recurrence rate at 2.4%, making it a safer option among biological materials.

References

  1. Boom MA et al. A Systematic Review of Graft-Related Complications and Recurrence Following Minimally Invasive Sacrocolpopexy With Xenografts and Allografts. BJOG. 2026 Mar 02. doi: 10.1111/1471-0528.70184. PMID: 41771773.
  2. Sohlberg E, et al. Reoperation rates for pelvic organ prolapse repairs with biologic and synthetic grafts in a large population-based cohort. Int Urogynecol J. 2020 Feb;31(2):291-301. doi: 10.1007/s00192-019-04035-3.
  3. Nygaard I, et al. Long-term outcomes following abdominal sacrocolpopexy for pelvic organ prolapse. JAMA. 2013 May 15;309(19):2016-24. doi: 10.1001/jama.2013.4919.